3:I[231,["231","static/chunks/231-0fefb1d35a503081.js","669","static/chunks/app/asx/%5Bticker%5D/page-f6c15ab6b5482fb0.js"],""]
4:I[9275,[],""]
6:I[1343,[],""]
7:I[8173,["231","static/chunks/231-0fefb1d35a503081.js","410","static/chunks/410-427e639415368772.js","185","static/chunks/app/layout-cc68188960cc2107.js"],"Image"]
2:T58f,{"@context":"https://schema.org","@type":"FAQPage","mainEntity":[{"@type":"Question","name":"What does PER do?","acceptedAnswer":{"@type":"Answer","text":"Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company focused on developing novel psychedelic medicines, specifically its lead compound PER-003, for the treatment of mental health conditions such as Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)."}},{"@type":"Question","name":"Is PER a good investment?","acceptedAnswer":{"@type":"Answer","text":"Investing in Percheron Therapeutics is highly speculative, typical for clinical-stage biotechnology companies with a micro-cap valuation. It offers significant upside potential if its drug candidates succeed in trials and gain regulatory approval, but also carries high risks of clinical failure, funding challenges, and intense competition, making it suitable only for investors with a high-risk tolerance and long-term horizon."}},{"@type":"Question","name":"What drives PER's share price?","acceptedAnswer":{"@type":"Answer","text":"PER's share price is primarily driven by announcements of clinical trial results (positive or negative), progress in regulatory submissions and approvals, success in securing adequate funding through capital raises, and any news regarding strategic partnerships or licensing agreements for its drug candidates."}}]}5:["ticker","PER","d"]
0:["expxC_2cvqaJFzWCHYH4M",[[["",{"children":["asx",{"children":[["ticker","PER","d"],{"children":["__PAGE__?{\"ticker\":\"PER\"}",{}]}]}]},"$undefined","$undefined",true],["",{"children":["asx",{"children":[["ticker","PER","d"],{"children":["__PAGE__",{},[["$L1",["$","div",null,{"className":"space-y-12","children":[["$","script",null,{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"$2"}}],["$","section",null,{"className":"grid gap-8 lg:grid-cols-[1.6fr_0.8fr]","children":[["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"Health Care"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":["Percheron Therapeutics Limited"," (","PER",")"]}],["$","p",null,{"className":"mt-4 text-sm text-slate-300","children":"Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company focused on developing novel psychedelic medicines for the treatment of various mental health conditions. Its lead program, PER-003, is being advanced for indications such as Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD), aiming to address significant unmet medical needs."}],["$","div",null,{"className":"mt-6 grid gap-4 sm:grid-cols-2","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Market Cap"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"A$9M"}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-xs text-slate-500","children":"Shares on Issue"}],["$","p",null,{"className":"mt-2 text-lg font-semibold","children":"N/A"}]]}]]}],["$","div",null,{"className":"mt-6 flex flex-wrap gap-3 text-xs text-slate-400","children":[["$","a",null,{"href":"","className":"rounded-full border border-white/10 px-3 py-1","children":"Company Website"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"AI coverage updated hourly"}],["$","span",null,{"className":"rounded-full border border-white/10 px-3 py-1","children":"Data from ASX filings"}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"Price Chart (TradingView)"}],["$","div",null,{"className":"mt-4 h-72 rounded-xl border border-dashed border-blue-500/30 bg-ink-900/40 p-6 text-sm text-slate-400","children":["Embed TradingView widget here for ","PER",". The production version should load live pricing and technical indicators."]}]]}],["$","section",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h2",null,{"className":"font-display text-xl font-semibold","children":"AI Analysis"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm text-slate-300","children":[["$","p","As a micro-cap biotechnology firm with a market capitalization of A$9 million, Percheron Therapeutics is currently in the clinical development phase, primarily focused on advancing its psychedelic medicine pipeline. The company is pre-revenue, with its financial performance largely characterized by R&D expenditure and cash burn associated with preclinical and clinical trials rather than profitability. Key metrics for investors typically revolve around the company's cash runway and progress in drug development rather than traditional earnings.",{"children":"As a micro-cap biotechnology firm with a market capitalization of A$9 million, Percheron Therapeutics is currently in the clinical development phase, primarily focused on advancing its psychedelic medicine pipeline. The company is pre-revenue, with its financial performance largely characterized by R&D expenditure and cash burn associated with preclinical and clinical trials rather than profitability. Key metrics for investors typically revolve around the company's cash runway and progress in drug development rather than traditional earnings."}],["$","p","The growth outlook for Percheron Therapeutics is highly speculative and contingent on the successful progression of its clinical assets through various trial phases and eventual regulatory approval. Upcoming catalysts include the announcement of preclinical or clinical trial results for PER-003, patient recruitment updates, and any potential partnerships or licensing agreements. The strategic direction is firmly centered on funding and advancing its lead compounds towards commercialisation, which will likely involve further capital raises to sustain operations.",{"children":"The growth outlook for Percheron Therapeutics is highly speculative and contingent on the successful progression of its clinical assets through various trial phases and eventual regulatory approval. Upcoming catalysts include the announcement of preclinical or clinical trial results for PER-003, patient recruitment updates, and any potential partnerships or licensing agreements. The strategic direction is firmly centered on funding and advancing its lead compounds towards commercialisation, which will likely involve further capital raises to sustain operations."}]]}]]}],["$","div",null,{"className":"grid gap-6 lg:grid-cols-2","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-emerald-300","children":"Bull Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Positive Phase 2 clinical trial results for PER-003 demonstrating efficacy and safety for target indications like MDD or PTSD.",{"children":["• ","Positive Phase 2 clinical trial results for PER-003 demonstrating efficacy and safety for target indications like MDD or PTSD."]}],["$","li","Securing a significant partnership or licensing deal with a larger pharmaceutical company, validating its technology and providing non-dilutive funding.",{"children":["• ","Securing a significant partnership or licensing deal with a larger pharmaceutical company, validating its technology and providing non-dilutive funding."]}],["$","li","Successful completion of a capital raise ensuring sufficient funding for future clinical development milestones and extending its operational runway.",{"children":["• ","Successful completion of a capital raise ensuring sufficient funding for future clinical development milestones and extending its operational runway."]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"flex items-center gap-2 text-sm font-semibold text-red-300","children":"Bear Case"}],["$","ul",null,{"className":"mt-4 space-y-2 text-sm text-slate-300","children":[["$","li","Failure of PER-003 to meet primary or secondary endpoints in clinical trials, leading to program delays or termination.",{"children":["• ","Failure of PER-003 to meet primary or secondary endpoints in clinical trials, leading to program delays or termination."]}],["$","li","Inability to secure adequate funding for ongoing R&D and clinical operations, potentially leading to significant shareholder dilution or the inability to progress its pipeline.",{"children":["• ","Inability to secure adequate funding for ongoing R&D and clinical operations, potentially leading to significant shareholder dilution or the inability to progress its pipeline."]}],["$","li","Increased regulatory hurdles or heightened competition within the rapidly evolving psychedelic medicine sector, impacting market potential and timeline to commercialisation.",{"children":["• ","Increased regulatory hurdles or heightened competition within the rapidly evolving psychedelic medicine sector, impacting market potential and timeline to commercialisation."]}]]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Recent Announcements"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Quarterly Activities Report"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Highlights production updates, capital allocation priorities, and FY guidance commentary."}]]}],["$","div",null,{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"font-semibold","children":"Investor Presentation"}],["$","p",null,{"className":"text-xs text-slate-500","children":"Strategic outlook with market positioning and growth pipeline."}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"FAQs"}],["$","div",null,{"className":"mt-4 space-y-3 text-sm text-slate-300","children":[["$","div","What does PER do?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What does PER do?"}],["$","p",null,{"className":"text-slate-400","children":"Percheron Therapeutics Limited (ASX: PER) is an Australian clinical-stage biotechnology company focused on developing novel psychedelic medicines, specifically its lead compound PER-003, for the treatment of mental health conditions such as Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)."}]]}],["$","div","Is PER a good investment?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"Is PER a good investment?"}],["$","p",null,{"className":"text-slate-400","children":"Investing in Percheron Therapeutics is highly speculative, typical for clinical-stage biotechnology companies with a micro-cap valuation. It offers significant upside potential if its drug candidates succeed in trials and gain regulatory approval, but also carries high risks of clinical failure, funding challenges, and intense competition, making it suitable only for investors with a high-risk tolerance and long-term horizon."}]]}],["$","div","What drives PER's share price?",{"className":"border-b border-white/5 pb-3","children":[["$","p",null,{"className":"font-semibold text-white","children":"What drives PER's share price?"}],["$","p",null,{"className":"text-slate-400","children":"PER's share price is primarily driven by announcements of clinical trial results (positive or negative), progress in regulatory submissions and approvals, success in securing adequate funding through capital raises, and any news regarding strategic partnerships or licensing agreements for its drug candidates."}]]}]]}]]}]]}],["$","div",null,{"className":"space-y-6","children":[["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-semibold","children":"Key Metrics"}],["$","div",null,{"className":"mt-4 space-y-4 text-sm","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Share Price"}],["$","span",null,{"className":"font-semibold","children":["A$","0.02"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"1Y Performance"}],["$","span",null,{"className":"font-semibold text-emerald-400","children":["29.0","%"]}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Market Cap"}],["$","span",null,{"className":"font-semibold","children":"A$9M"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Shares on Issue"}],["$","span",null,{"className":"font-semibold","children":"N/A"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"Sector"}],["$","span",null,{"className":"font-semibold","children":"Health Care"}]]}],["$","div",null,{"className":"flex items-center justify-between","children":[["$","span",null,{"className":"text-slate-400","children":"IPO Date"}],["$","span",null,{"className":"font-semibold","children":"20/12/2001"}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Compare ASX Brokers"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Find the best trading platform for your needs. We review fees, features, and research tools."}],["$","div",null,{"className":"mt-4 grid gap-3 sm:grid-cols-2","children":[["$","div","AlphaTrade",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"AlphaTrade"}],["$","p",null,{"className":"text-xs text-slate-400","children":"$$0 brokerage on ETFs"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","MarketPilot",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"MarketPilot"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Advanced research suite"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Coastline",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Coastline"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Low FX fees"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}],["$","div","Harbour",{"className":"rounded-xl border border-white/10 bg-ink-900/40 p-4","children":[["$","p",null,{"className":"text-sm font-semibold text-white","children":"Harbour"}],["$","p",null,{"className":"text-xs text-slate-400","children":"Pro-level charting"}],["$","button",null,{"className":"mt-3 w-full rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}]]}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"Sponsored links. We may receive compensation if you open an account."}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"Related Stocks"}],["$","div",null,{"className":"mt-4 space-y-4","children":[["$","$L3",null,{"href":"/asx/CSL","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["CSL",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"CSL Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","285.40"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["9.1","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"CSL is a global biotechnology leader focused on plasma-derived therapies, vaccines, and specialty biologics."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$140B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/PNV","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["PNV",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Polynovo Ltd"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","1.66"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["14.7","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Polynovo manufactures innovative wound care products used in burns, trauma, and reconstructive surgery."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$2.4B"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}],["$","$L3",null,{"href":"/asx/1AD","className":"glass-card group rounded-2xl p-5 transition hover:-translate-y-1 hover:border-blue-500/40","children":[["$","div",null,{"className":"flex items-center justify-between","children":[["$","div",null,{"children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.2em] text-slate-500","children":"Health Care"}],["$","h3",null,{"className":"mt-2 font-display text-lg font-semibold","children":["1AD",["$","span",null,{"className":"ml-2 text-sm text-slate-400","children":"Adalta Limited"}]]}]]}],["$","div",null,{"className":"text-right","children":[["$","p",null,{"className":"text-sm text-slate-300","children":["A$","0.09"]}],["$","p",null,{"className":"text-xs font-semibold text-emerald-400","children":["37.0","% 1Y"]}]]}]]}],["$","p",null,{"className":"mt-4 text-sm text-slate-400","children":"Adalta Limited is a clinical-stage biotechnology company developing its proprietary i-body technology platform for treating a range of diseases. Based in Australia, its lead product candidate, AD-214, is being developed to treat Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases."}],["$","div",null,{"className":"mt-4 flex items-center justify-between text-xs text-slate-500","children":[["$","span",null,{"children":["Market cap ","A$11M"]}],["$","span",null,{"className":"text-blue-300","children":"View analysis"}]]}]]}]]}]]}]]}]]}]]}]],null],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children","$5","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children","asx","children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":"$undefined","notFoundStyles":"$undefined","styles":null}],null]},[["$","html",null,{"lang":"en","className":"__variable_6d343d __variable_49a339","children":[["$","head",null,{"children":["$","link",null,{"rel":"icon","href":"/logo.svg","type":"image/svg+xml"}]}],["$","body",null,{"className":"min-h-screen bg-ink-900 text-slate-100","children":["$","div",null,{"className":"grid-glow min-h-screen","children":[["$","header",null,{"className":"sticky top-0 z-50 border-b border-white/10 bg-ink-800/80 backdrop-blur","children":[["$","div",null,{"className":"mx-auto flex w-full max-w-6xl items-center justify-between px-4 py-4 sm:px-6 lg:px-8","children":[["$","$L3",null,{"href":"/","className":"flex items-center gap-3","children":[["$","$L7",null,{"src":"/logo.svg","alt":"ASX Desk","width":140,"height":40,"className":"h-10 w-auto","priority":true}],["$","span",null,{"className":"hidden text-xs uppercase tracking-[0.2em] text-slate-400 sm:inline","children":"Research Terminal"}]]}],["$","nav",null,{"className":"hidden items-center gap-6 text-sm text-slate-300 md:flex","children":[["$","$L3","/",{"href":"/","className":"transition hover:text-white","children":"Home"}],["$","$L3","/screener",{"href":"/screener","className":"transition hover:text-white","children":"Screener"}],["$","$L3","/sectors/materials",{"href":"/sectors/materials","className":"transition hover:text-white","children":"Sectors"}],["$","$L3","/news",{"href":"/news","className":"transition hover:text-white","children":"News"}],["$","$L3","/compare/BHP-vs-RIO",{"href":"/compare/BHP-vs-RIO","className":"transition hover:text-white","children":"Compare"}],["$","$L3","/about",{"href":"/about","className":"transition hover:text-white","children":"About"}]]}],["$","div",null,{"className":"hidden items-center gap-3 sm:flex","children":[["$","button",null,{"className":"rounded-full border border-blue-500/40 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-blue-200 shadow-glow transition hover:bg-blue-500/20","children":"Premium Research"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white shadow-glow transition hover:bg-blue-400","children":"Open Account"}]]}]]}],["$","div",null,{"className":"flex items-center justify-between border-t border-white/5 px-4 py-3 text-xs text-slate-400 md:hidden","children":[["$","span",null,{"children":"AI market insights for ASX investors"}],["$","$L3",null,{"href":"/screener","className":"text-blue-300","children":"Screener"}]]}]]}],["$","main",null,{"className":"mx-auto w-full max-w-6xl px-4 pb-20 pt-6 sm:px-6 lg:px-8","children":["$","$L4",null,{"parallelRouterKey":"children","segmentPath":["children"],"error":"$undefined","errorStyles":"$undefined","errorScripts":"$undefined","template":["$","$L6",null,{}],"templateStyles":"$undefined","templateScripts":"$undefined","notFound":["$","div",null,{"className":"flex min-h-[60vh] flex-col items-center justify-center text-center","children":[["$","p",null,{"className":"text-xs uppercase tracking-[0.3em] text-blue-300","children":"404"}],["$","h1",null,{"className":"mt-3 font-display text-3xl font-semibold","children":"Page not found"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"We couldn't locate that ASX page. Try searching a ticker or visit the homepage."}],["$","$L3",null,{"href":"/","className":"mt-6 rounded-full bg-blue-500 px-6 py-3 text-xs font-semibold uppercase tracking-wide text-white","children":"Back to Home"}]]}],"notFoundStyles":[],"styles":null}]}],["$","footer",null,{"className":"border-t border-white/10 bg-ink-800/60","children":[["$","div",null,{"className":"mx-auto grid w-full max-w-6xl gap-8 px-4 py-12 sm:px-6 lg:grid-cols-3 lg:px-8","children":[["$","div",null,{"children":[["$","h3",null,{"className":"font-display text-lg font-semibold","children":"ASX Desk"}],["$","p",null,{"className":"mt-3 text-sm text-slate-400","children":"Automated ASX stock research with AI-generated analysis, sector trends, and data-backed screening tools."}],["$","div",null,{"className":"mt-4 flex gap-3","children":[["$","button",null,{"className":"rounded-full bg-blue-500 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Open an Account"}],["$","button",null,{"className":"rounded-full border border-white/10 px-4 py-2 text-xs font-semibold uppercase tracking-wide text-slate-300","children":"Download Media Kit"}]]}]]}],["$","div",null,{"className":"grid grid-cols-2 gap-6 text-sm text-slate-400","children":[["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Platform"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/screener","className":"hover:text-white","children":"Screener"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/news","className":"hover:text-white","children":"News & Commentary"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/about","className":"hover:text-white","children":"About"}]}]]}]]}],["$","div",null,{"children":[["$","h4",null,{"className":"mb-2 font-semibold text-slate-200","children":"Sectors"}],["$","ul",null,{"className":"space-y-2","children":[["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/materials","className":"hover:text-white","children":"Materials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/financials","className":"hover:text-white","children":"Financials"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/health care","className":"hover:text-white","children":"Health Care"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/information technology","className":"hover:text-white","children":"Information Tech"}]}],["$","li",null,{"children":["$","$L3",null,{"href":"/sectors/energy","className":"hover:text-white","children":"Energy"}]}]]}]]}]]}],["$","div",null,{"className":"glass-card rounded-2xl p-6","children":[["$","h4",null,{"className":"font-semibold","children":"Weekly Alpha Briefing"}],["$","p",null,{"className":"mt-2 text-sm text-slate-400","children":"Get our AI-powered watchlist, sector heatmaps, and new ASX coverage in your inbox."}],["$","div",null,{"className":"mt-4 flex flex-col gap-3 sm:flex-row","children":[["$","input",null,{"type":"email","placeholder":"you@example.com","className":"w-full rounded-full border border-white/10 bg-ink-900/60 px-4 py-2 text-sm text-white placeholder:text-slate-500"}],["$","button",null,{"className":"rounded-full bg-blue-500 px-5 py-2 text-xs font-semibold uppercase tracking-wide text-white","children":"Subscribe"}]]}],["$","p",null,{"className":"mt-3 text-xs text-slate-500","children":"By subscribing you agree to receive marketing updates. Unsubscribe anytime."}]]}]]}],["$","div",null,{"className":"border-t border-white/10 py-6 text-center text-xs text-slate-500","children":["$","p",null,{"children":"General advice only. This site does not consider your objectives, financial situation, or needs. Past performance is not indicative of future results."}]}]]}]]}]}]]}],null],null],[[["$","link","0",{"rel":"stylesheet","href":"/_next/static/css/7c1fda61599f9f98.css","precedence":"next","crossOrigin":"$undefined"}]],[null,"$L8"]]]]]
8:[["$","meta","0",{"name":"viewport","content":"width=device-width, initial-scale=1"}],["$","meta","1",{"charSet":"utf-8"}],["$","title","2",{"children":"PER share price, analysis & company profile - Percheron Therapeutics Limited | ASX Desk"}],["$","meta","3",{"name":"description","content":"Latest PER share price overview, what Percheron Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","link","4",{"rel":"canonical","href":"https://asxdesk.com/asx/PER/"}],["$","meta","5",{"property":"og:title","content":"PER share price, analysis & company profile - Percheron Therapeutics Limited"}],["$","meta","6",{"property":"og:description","content":"Latest PER share price overview, what Percheron Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","7",{"property":"og:url","content":"https://asxdesk.com/asx/PER/"}],["$","meta","8",{"property":"og:type","content":"article"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"PER share price, analysis & company profile - Percheron Therapeutics Limited"}],["$","meta","11",{"name":"twitter:description","content":"Latest PER share price overview, what Percheron Therapeutics Limited does, bull and bear cases, and AI-powered analysis for ASX investors."}],["$","meta","12",{"name":"next-size-adjust"}]]
1:null
